New hope for kidney patients: drug safely lowers dangerous potassium levels

NCT ID NCT05136664

Completed Disease control Sponsor: Vifor Fresenius Medical Care Renal Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called patiromer in 262 Chinese adults with chronic kidney disease and high potassium levels. Participants took patiromer for 4 weeks, then some switched to placebo for 8 weeks to see if potassium stayed controlled. The goal was to manage potassium safely while allowing patients to continue their heart-protective medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hyperkalemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERKALEMIA RENAL INSUFFICIENCY CHRONIC

Contacts and locations

Locations

Investigator Site 001

Hangzhou, Zhejiang, 310003, China
Investigator Site 002

Changzhou, Jiangsu, 213004, China
Investigator Site 003

Lanzhou, Gansu, 730030, China
Investigator Site 004

Chengdu, Sichuan, 610044, China
Investigator Site 005

Xuzhou, Jiangsu, 221004, China
Investigator Site 006

Changsha, Hunan, 410013, China
Investigator Site 007

Changchun, Jilin, 130041, China
Investigator Site 008

Hefei, Anhui, 230601, China
Investigator Site 009

Hefei, Anhui, 230022, China
Investigator Site 010

Wuhan, Hubei, 430060, China
Investigator Site 011

Yuncheng, Shanxi, 044099, China
Investigator Site 012

Lanzhou, Gansu, 730013, China
Investigator Site 013

Zhenjiang, Jiangsu, 210031, China
Investigator Site 014

Tianjin, Tianjin Municipality, 300052, China
Investigator Site 015

Shanghai, Shanghai Municipality, 200040, China
Investigator Site 016

Beijing, Beijing Municipality, 100029, China
Investigator Site 018

Yinchuan, Ningxia, 750003, China
Investigator Site 019

Nanjing, Jiangsu, 210029, China
Investigator Site 020

Hanzhou, Zhejiang, 310014, China
Investigator Site 021

Wuxi, Jiangsu, 214023, China
Investigator Site 022

Taiyuan, Shanxi, 030012, China
Investigator Site 023

Ürümqi, Xinjiang, 830001, China
Investigator Site 024

Nanyang, Henan, 473000, China
Investigator Site 025

Jinhua, Zhejiang, 322000, China
Investigator Site 026

Jiaxing, Zhejiang, 314000, China
Investigator Site 027

Zhuzhou, Tianyuan District, 412007, China
Investigator Site 028

Shanghai, Pudong New Area, 200120, China
Investigator Site 030

Nanning, Guangxi, 530000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.